05:45 PM EDT, 04/30/2024 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said late Tuesday the US Food and Drug Administration approved the Ingrezza Sprinkle capsules to treat adults with tardive dyskinesia and chorea related to Huntington's disease.

Tardive dyskinesia is a movement disorder, while Huntington's disease is a neurodegenerative disorder.

The company said the capsules offer an alternative option for patients who experience dysphagia or have difficulty swallowing.

Neurocrine shares were up over 5% in after-hours activity.

Price: 145.00, Change: +7.46, Percent Change: +5.42